Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Singer, Andrew C ^a   Järhult, Josef D ^b   Grabic, Roman ^c,d   Khan, Ghazanfar A ^c   Lindberg, Richard H ^c   Fedorova, Ganna ^c,d   Fick, Jerker ^c   Bowes, Michael J ^a   Olsen, Björn ^b,e   Söderström, Hanna ^c  

^a NATURAL ENVIRONMENT RESEARCH COUNCIL   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^e LINNAEUS UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; NAPHAZOLINE; NORFLOXACIN; OFLOXACIN; OXYMETAZOLINE; OXYTETRACYCLINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; XYLOMETAZOLINE; ANTIINFECTIVE AGENT; DECONGESTIVE AGENT; WASTE WATER; WATER POLLUTANT;

ARTICLE; AUTUMN; CONTROLLED STUDY; DRUG DETERMINATION; DRUG USE; EFFLUENT; INFLUENZA A (H1N1); LIMIT OF DETECTION; LIMIT OF QUANTITATION; PANDEMIC INFLUENZA; RIVER; SLUDGE TREATMENT; UNITED KINGDOM; WASTE WATER TREATMENT PLANT; WATER ANALYSIS; WATER POLLUTION; WATER SAMPLING; CHEMISTRY; ENVIRONMENTAL MONITORING; GEOGRAPHY; WASTE WATER; WATER POLLUTANT;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; ENGLAND; ENVIRONMENTAL MONITORING; GEOGRAPHY; NASAL DECONGESTANTS; RIVERS; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84907584501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108621     Document Type: Article

References (60)

1. Azuma T, Nakada N, Yamashita N, Tanaka H (2013) Mass balance of antiinfluenza drugs discharged into the Yodo River system, Japan, under an influenza outbreak. Chemosphere 93: 1672-1677.
2. Singer AC, Colizza V, Schmitt H, Andrews J, Balcan D, et al. (2011) Assessing the ecotoxicologic hazards of a pandemic influenza medical response. Environ Health Perspect 119: 1084-1090.
3. Chang CC, Cheng AC, Chang AB (2014) Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev 3: CD006088.
4. Dollery C (1999) Therapeutic Drugs. London: Harcourt Brace and Company Limited.
5. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-1041.
6. Edlund A, Ek K, Breitholtz M, Gorokhova E (2012) Antibiotic-induced change of bacterial communities associated with the copepod Nitocra spinipes. PLoS One 7: e33107.
7. Singer AC, Nunn MA, Gould EA, Johnson AC (2007) Potential risks associated with the proposed widespread use of Tamiflu. Environmental Health Perspectives 115: 102-106.
8. Escher BI, Bramaz N, Lienert J, Neuwoehner J, Straub JO (2010) Mixture toxicity of the antiviral drug Tamiflu) (oseltamivir ethylester) and its active metabolite oseltamivir acid. Aquat Toxicol 96: 194-202.
9. Straub JO (2009) An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Ecotoxicol Environ Saf 72: 1625-1634.
10. Hutchinson TH, Beesley A, Frickers PE, Readman JW, Shaw JP, et al. (2009) Extending the environmental risk assessment for oseltamivir (Tamiflu) under pandemic use conditions to the coastal marine compartment. Environ Int 35: 931-936.
11. Chen WY, Lin CJ, Liao CM (2014) Assessing exposure risks for aquatic organisms posed by Tamiflu use under seasonal influenza and pandemic conditions. Environ Pollut 184: 377-384.
12. Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B (2009) Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 75: 28-33.
13. Slater FR, Singer AC, Turner S, Barr JJ, Bond PL (2011) Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu) and loss of nutrient removal performance. FEMS Microbiol Lett 315: 17-22.
14. Singer AC, Howard BM, Johnson AC, Knowles CJ, Jackman S, et al. (2008) Meeting report: risk assessment of tamiflu use under pandemic conditions. Environ Health Perspect 116: 1563-1567.
15. Achenbach JE, Bowen RA (2013) Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks. Antimicrob Agents Chemother 57: 2171-2181.
16. Jarhult JD (2012) Oseltamivir (Tamiflu) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans - a review. Infect Ecol Epidemiol 2.
17. Gillman A, Muradrasoli S, Söderström H, Nordh J, Bröjer C, et al. (2013) Resistance Mutation R292K Is Induced in Influenza A(H6N2) Virus by Exposure of Infected Mallards to Low Levels of Oseltamivir. PLoS ONE 8: e71230.
18. Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, et al. (2011) Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One 6: e24742.
19. Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, et al. (2013) The role of the natural environment in the emergence of antibiotic resistance in gramnegative bacteria. Lancet Infect Dis 13: 155-165.
20. Gaze WH, Krone SM, Larsson DG, Li XZ, Robinson JA, et al. (2013) Influence of humans on evolution and mobilization of environmental antibiotic resistome. Emerg Infect Dis 19.
21. World Health Organization (2010) WHO recommendations for the post-pandemic period: Pandemic (H1N1) 2009 briefing note 23. Available: http://www.who.int/csr/disease/swineflu/notes/briefing-20100810/en/. Accessed 2012 Jun 1.
22. Bowes MJ, Jarvie HP, Naden PS, Old GH, Scarlett PM, et al. (2014) Identifying priorities for nutrient mitigation using river concentration-flow relationships: The Thames basin, UK. Journal of Hydrology 517: 1-12.
23. Harvey CL, Dixon H, Hannaford J (2012) An appraisal of the performance of data-infilling methods for application to daily mean river flow records in the UK. Hydrology Research 43: 618-636.
24. TuTiempo.net (2009) Climate: Benson (November, 2009). Available: http://www.tutiempo.net/en/Climate/Benson/11-2009/36580.htm. Accessed 2012 Oct 26.
25. Prasse C, Schlusener MP, Schulz R, Ternes TA (2010) Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ Sci Technol 44: 1728-1735.
26. Balcan D, Colizza V, Singer AC, Chouaid C, Hu H, et al. (2009) Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic. PLoS Curr 1: RRN1133.
27. Khan GA, Lindberg R, Grabic R, Fick J (2012) The development and application of a system for simultaneously determining anti-infectives and nasal decongestants using on-line solid-phase extraction and liquid chromatographytandem mass spectrometry. J Pharm Biomed Anal 66: 24-32.
28. NHS BSA (2011) Prescribing Analysis Charts: National Antibiotics Charts. Available: http://www.nhsbsa.nhs.uk/PrescriptionServices/2587.aspx. Accessed 2012 Oct.
29. NHS Information Centre for Health and Social Care (2011) Number of GP Prescriptions by drug by postcode. Available: http://data.gov.uk/apps/number-of-gp-prescriptions-by-drug-by-postcode.
30. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the UK (April 2009 - May 2010). Available: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1284475321350. Accessed 2012 Jun 1.
31. Rogers S, Sedghi A (2011) Swine flu data in the UK: see how bad cases are where you live. Guardian Available: http://www.guardian.co.uk/news/datablog/2011/jan/06/swine-flu-data-uk#data. Accessed 2012 Jun 1.
32. The Health and Social Care Information Centre PSU (2012) Average Daily Quantities. Available: http://www.ic.nhs.uk/services/prescribing-support-unit-psu/using-the-service/reference/measures/volume-measures/average-daily-quantities-adq. Accessed 2012 Oct 19.
33. Davey P, Ferech M, Ansari F, Muller A, Goossens H (2008) Outpatient antibiotic use in the four administrations of the UK: cross-sectional and longitudinal analysis. Journal of Antimicrobial Chemotherapy 62: 1441-1447.
34. Singer AC, Jarhult JD, Grabic R, Khan GA, Fedorova G, et al. (2013) Compliance to oseltamivir among two populations in Oxfordshire, United Kingdom affected by influenza A(H1N1) pdm09, November 2009 - a waste water epidemiology study. PLoS One 8: e60221.
35. Azuma T, Nakada N, Yamashita N, Tanaka H (2012) Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environ Sci Technol 46: 12873-12881.
36. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S (2012) Antiviral Drugs Zanamivir and Oseltamivir Found in Wastewater and Surface Water in Osaka, Japan. Journal of Water and Environment Technology 10: 57-68.
37. Leknes H, Sturtzel IE, Dye C (2012) Environmental release of oseltamivir from a Norwegian sewage treatment plant during the 2009 influenza A (H1N1) pandemic. Sci Total Environ 414: 632-638.
38. Ghosh GC, Nakada N, Yamashita N, Tanaka H (2010) Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere 81: 13-17.
39. Ghosh GC, Nakada N, Yamashita N, Tanaka H (2010) Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 118: 103-107.
40. Fick J, Lindberg RH, Tysklind M, Haemig PD, Waldenstrom J, et al. (2007) Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2: e986.
41. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S (2010) Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya River, Osaka Japan. Journal of Water and Environment Technology 8: 363-372.
42. Kohring GW, Rogers JE, Wiegel J (1989) Anaerobic biodegradation of 2,4-dichlorophenol in freshwater lake sediments at different temperatures. Applied and Environmental Microbiology 55: 348-353.
43. Atlas RM (1975) Effects of Temperature and Crude Oil Composition on Petroleum Biodegradation. Applied Microbiology 30: 396-403.
44. Michael I, Rizzo L, McArdell CS, Manaia CM, Merlin C, et al. (2013) Urban wastewater treatment plants as hotspots for the release of antibiotics in the environment: a review. Water Res 47: 957-995.
45. Luo Y, Guo W, Ngo HH, Nghiem LD, Hai FI, et al. (2014) A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment. Sci Total Environ 473-474: 619-641.
46. Lindberg RH, Ostman M, Olofsson U, Grabic R, Fick J (2014) Occurrence and behaviour of 105 active pharmaceutical ingredients in sewage waters of a municipal sewer collection system. Water Res 58C: 221-229.
47. Kardas P (2002) Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother 49: 897-903.
48. Llor C, Hernandez S, Bayona C, Moragas A, Sierra N, et al. (2013) A study of adherence to antibiotic treatment in ambulatory respiratory infections. Int J Infect Dis 17: e168-172.
49. McNulty CA, Boyle P, Nichols T, Clappison P, Davey P (2007) The public's attitudes to and compliance with antibiotics. J Antimicrob Chemother 60 Suppl 1: i63-68.
50. Ort C, Lawrence MG, Reungoat J, Mueller JF (2010) Sampling for PPCPs in wastewater systems: comparison of different sampling modes and optimization strategies. Environ Sci Technol 44: 6289-6296.
51. Ort C, Gujer W (2006) Sampling for representative micropollutant loads in sewer systems. Water Sci Technol 54: 169-176.
52. Ort C, Schaffner C, Giger W, Gujer W (2005) Modeling stochastic load variations in sewer systems. Water Sci Technol 52: 113-122.
53. Ort C, Lawrence MG, Rieckermann J, Joss A (2010) Sampling for pharmaceuticals and personal care products (PPCPs) and illicit drugs in wastewater systems: are your conclusions valid? A critical review. Environ Sci Technol 44: 6024-6035.
54. Gillman A, Muradrasoli S, Soderstrom H, Nordh J, Brojer C, et al. (2013) Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS One 8: e71230.
55. Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Yamanushkin PM, Bichko VV, et al. (2013) A novel influenza virus neuraminidase inhibitor AV5027. Antiviral Res 100: 698-708.
56. Wathen MW, Barro M, Bright RA (2013) Antivirals in seasonal and pandemic influenza-future perspectives. Influenza Other Respir Viruses 7 Suppl 1: 76-80.
57. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, et al. (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 4: CD008965.
58. Drinking Water Inspectorate (2007) Desk based review of current knowledge on pharmaceuticals in drinking water and estimation of potential levels (Defra Project Code: CSA 7184/WT02046/DWI70/2/213). Available: http://googl/nkBVlP.
59. Perelson AS, Rong L, Hayden FG (2012) Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human Infections. Journal of Infectious Diseases 205: 1642-1645.
60. Kim W-Y, Young Suh G, Huh JW, Kim S-H, Kim M-j, et al. (2011) Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation. Antimicrobial Agents and Chemotherapy 55: 5703-5709.